Fda Accepts Eisai Filing Of A Supplemental Biologics License Application And Grants Priority Review For Traditional Approval Of Leqembi
Confirmatory Phase 3 Clarity Ad Data To Be Evaluated By Fda In Determining Whether To Convert Accelerated Approval Of Leqembi To A Traditional ApprovalPriority Review Accelerates Fda Review Time With A Prescription Drug User Fee Act (Pdufa) Target Action On July 6, 2023 Eisai Co., Ltd. And Biogen Inc. Announced Today That The U.S. Food And Drug Administration (Fda) Has Accepted Eisai
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!